Methods: Demographic data, tumor molecular characteristics and overall survival in both groups were also assessed. Furthermore, in this study, we evaluated the expression of IL-18 and p50 nuclear fraction of NF-B by immunohistochemistry in specimens from IBC and LABC (T4b).
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The most aggressive type of locally advanced breast cancer is clinically classified as inflammatory breast carcinoma (IBC). 3 Women diagnosed with IBC have an average five-year survival of 30-40%, whereas patients with noninflammatory locally advanced breast cancer (LABC) the average survival in five-year is 70-80%. 4 The IBC has been called "inflammatory" because the breast often shows signs of inflammation such as redness, hyperthermia and edema. 5 The presence of inflammatory signs support the hypothesis that immune cells are involved in the carcinogenesis and/or tumor progression, and seem to be relevant to aggressiveness of IBC. In this context, tumor microenvironment-infiltrating cells possibly play an important role by secreting cytokines and other cellular mediators that can contribute to tumor progression. 6 Nuclear factor-kappa B (NF-B) is a cell-transducing transcription factor that regulates the inflammatory response, cytokine production and cell proliferation. [7] [8] [9] Dysregulated activation of NF-B may result in an amplified inflammatory response, altered balance of pro-and anti-apoptotic proteins and cell survival favoring tumor progression. 10 Interleukin-18 (IL-18) is one of the cytokines whose expression partially involves NF-B signaling. 11 The IL-18 is a proinflammatory cytokine that modulates the expression of adhesion molecules, nitric oxide synthase and chemokine production. 12 Interestingly, serum levels of IL-18 were found increased in breast cancer patients. 13 In addition, IL-18 expression was described in tumor and surrounding tumor tissues. 13 However, whether IL-18 expression accounts for a worsen prognosis in IBC and LABC breast cancer subtypes is still to be investigated.
Then, we aimed to investigate the expression of IL-18 and NF-B in tumor samples of IBC and LABC and the contribution of these inflammatory markers as prognostic factors and the impact on neoadjuvant chemotherapy response.
MATERIALS AND METHODS

Study characterization
This was an retrospective study including a series of 75 patients diag- 
Tumor samples
The tumor samples of patients with breast cancer were collected by core biopsy. The collected material was fixed in 10% formalin, embedded in paraffin, sectioned with 3-m thick and then stained with hematoxylin-eosin (H&E). Then, immunohistochemistry assay was performed for 29 and 28 samples of IBC and LABC, respectively.
Tissue Microarray
Tissue samples were obtained from the donor paraffin block with a manual puncher and arrayed in a matrix of six rows and three columns with up to 18 samples per recipient block. Liquid paraffin was gently added to melt the wax cylinders at 60 • C. Then, typical H&E staining and immunohistochemistry assay were performed. Two independent observers who were unaware of clinicopathological data conducted the analysis. The following score criteria for tumor and stromal cells, adapted from the previous publication, 14 were employed: zero expression (0), mild reaction (1+), moderate reaction (2+) and strong reaction (3+). Score analysis resulted in a high level of concordance (>90%).
Cases out of concordance were defined by consensus. The average value obtained for each sample was used to statistical analyzes. Slides were observed in an Olympus BX41 microscope.
Immunohistochemistry assay
Paraffin sections were dewaxed and rehydrated. Treatment with a 3% 
Statistical analysis
Patient and tumor characteristics were tabulated and stratified by breast cancer type (IBC vs LABC) and compared across groups with the chi-square test or Fisher's exact test when appropriate. For each crossing, the odds ratios with 95% of confidence interval were calculated.
Overall survival was calculated from the time of diagnosis to the date of death or the time of last follow-up. The survival curves were estimated with the Kaplan-Meier method and the log-rank test was used to test for differences between groups. The curves were confronted with variables RE, RP, C-erbB2 and triple negative by log-rank test. In addition, we used a multivariate analysis by the Cox regression model to identify the prognosis factors that independently affect the survival of the patients. P < 0.05 was considered significant. All data were analyzed using GraphPad Prism software version 6.01 and SPSS Statistics 22.0.
RESULTS
Clinico-pathological characterization of IBC versus LABC
As shown in Table 1 , there was no statistical difference (P = 0.324) between the IBC and LABC groups regarding the age of diagnosis.
The mean age observed for the IBC and LABC groups was 49 and 51, respectively. The characteristics of tumor specimens are also shown in Table 1 . The histology analysis showed that most of the tumors were invasive ductal carcinoma (IDC), which represents 85.3% of IBC cases and 90% of LABC. A similar distribution among histological grades was also observed, with approximately 90% of the IBC and LABC tumors classified as grades 2 and 3. Regarding the hormone receptors expression (ER, PR, C-erbB2 and triple negative), no statistical difference between the two groups was found.
Overall survival
The overall survival analysis showed that patients diagnosed with IBC showed a significant (P < 0.001) reduced survival when compared to patients with LABC ( Figure 1 ). The odds ratio of two-year survival from diagnosis of patients with IBC was 14.4 (95% confidence interval 3.5-58.9; Table S1) compared to patients with LABC. For five-year survival, the odds ratio was 6.61 (95% interval confidence 1.7-25.3; Table S1 ).
Despite no difference concerning locoregional recurrence (data not shown), patients with IBC clearly survived less (45.5% of patients died in two years) than patients with LABC (20.4%, P = 0.0002). Considering a five-year survival, 12.3% of patients with IBC are alive, whereas in the group of LABC this percentage was 37.6% (Figure 1 ). Figure 2A shows that LABC patients positive for estrogen receptor (ER + ) have a higher survival compared to the ER + IBC group. We observed that 50% of ER + LABC patients survived 4.4 years, whereas ER + IBC individuals survived only 2.3 years (P = 0.006). Regarding PR expression, no difference between the two populations was observed (P > 0.05, Figure 2B ). The contribution of C-erbB2 on patients' survival was also described. As observed in Figure 2C , IBC patients that were negative to C-erbB2 (C-erb2 − ) showed a worse prognosis (2.1-year median survival) compared to C-erb2-LABC group (4.4-year survival, P < 0.001). Triple negative patients were also assessed. As shown in Figure 2D , triple negative IBC patients also presented the worse prognosis (2-year survival) when compared to triple negative LABC group (3.4-year survival, P = 0.049). In multivariate analysis, the independent prognosis factors affecting the survival of patients with breast cancer the histologic grade 3 (P = 0.021) showed a survival rate 1.001 worse and the triple negative immune staining (P = 0.002) with a survival rate 1.004 worse (Table S2) . 
Overall survival according to the expression of tumor markers (ER, PR and C-erbB2) or triple negative patients
Immunohistochemistry to NF-B and IL-18
As shown in Table S3 , positive immunostaining to NF-B (score 2- (Tables S4 and S5) . A stronger positivity (score 2-3) was found in the stroma (27.6% of samples) when compared to IL-18-positive tumor cells (0%, P = 0.004; Table S3 ) in IBC group. Similar findings were observed in LABC group (50% in the stroma vs 3.5% in the tumor, P < 0.001; Table 4 ). However, when IL-18 immunostaining was compared in tumor (IBC: 0% vs LABC:
IL-18 immunostaining was also investigated
3.5%, P > 0.05) or in stroma (IBC: 27.6% vs LABC: 50%, P = 0.093), no statistical differences were detected (Table S4) . A representative photomicrograph is depicted in Figure 3 or for neoadjuvant chemotherapy response (P = 0.061; Table 2 ) was detected for both breast cancer subtypes IBC and LABC.
DISCUSSION
In this study was evaluated the expression of transcription factor NF- showed a mean age at diagnosis, which did not differ between the groups, although being higher than that observed in the present study, 57.2 years for IBC and 57.4 years for LABC. 15 These differences concerning the age at diagnosis might involve the population in study, genetic variability and environmental factors.
In regard to positivity for biomarkers (ER, PR and C-erbB2), no significant difference was observed between the two groups, which corroborates previously published data. 15 However, it is worth to note that positivity to ER represented a positive prognostic factor to LABC group compared with IBC ER + tumors, because a significantly higher overall survival was found in that group when compared to the IBC ER + group. Data from the SEER with a series of 2237 patients diagnosed with IBC and 7985 cases of LABC showed that ER + -expressing LABC patients have a significantly higher survival (80 months) compared to patients IBC that express ER, which survive an average of 60 months. 15 It is important to mention two aspects based on SEER study: (1) positivity to ER enhanced patients' survival of both LABC and IBC groups, which differed from the present study; (2) survival of North American patients are significantly higher than patients form this study. Such difference seems to rely on the time of diagnosis and access to primary health care. In Brazilian population, cancer diagnosis is commonly on advanced stage.
Here, we also found a similar C-erbB2 positivity for IBC and LABC (32.7% and 28.6%, respectively), which is in agreement with data observed in the study from the Royal Marsden Hospital in London that showed a 38% of C-erbB2 expression in IBC patients, 4 and the study from the MD Anderson Cancer Center identified 44.3% of IBC samples also positive to C-erbB2. 16 The absence of oncoprotein C-erbB2 expression has a significant impact on patient survival in IBC group compared to LABC. Interestingly, other studies have suggested that lack of C-erbB2 along with ER and PR negativity also significantly worsened the survival of patients in the IBC group when compared to LABC group. 17, 18 We also observed a mean survival of only 25 months (2. Apparently, the aggressiveness of the IBC seem also involve other immune system mechanisms, such as, IL-10, TGF-(Transforming Growth Factor Beta), regulatory T cells and M2 macrophages. These cells and mediators are responsible to regulate immune response tumor escape, leading to disease progression and metastasis. 6 Therefore, understanding the role of these mediators could help to identify specific markers for the IBC, what could explain the faster tumor progression and the shorter disease-free interval.
Immunity is now a major target for treating cancer. This study attempted to show IL-18 and NF-B as potential prognostic markers of neoadjuvant chemotherapy response in patients with IBC and LABC.
The lack of positive correlation might be related to small sample size or the population of study. Despite no statistical significance for the markers studied, the present research might be an important step for effective clinical management of breast cancer, because the role of other inflammatory markers that regulate immune function must be investigated. Additional studies are highly encouraged also with other ethnic groups.
CONCLUSION
In conclusion, the chemotherapy neoadjuvant complete response seems to be partially associated with IL-18 expression in stroma of IBC and LABC. 
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